Search Results - "CAMINIS, John"

Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis by Black, Dennis M, Delmas, Pierre D, Eastell, Richard, Reid, Ian R, Boonen, Steven, Cauley, Jane A, Cosman, Felicia, Lakatos, Péter, Leung, Ping Chung, Man, Zulema, Mautalen, Carlos, Mesenbrink, Peter, Hu, Huilin, Caminis, John, Tong, Karen, Rosario-Jansen, Theresa, Krasnow, Joel, Hue, Trisha F, Sellmeyer, Deborah, Eriksen, Erik Fink, Cummings, Steven R

“…In this double-blind, placebo-controlled trial, women with postmenopausal osteoporosis received an infusion of either zoledronic acid (5 mg) or placebo at…”
Get full text

Bone circuitry and interorgan skeletal crosstalk by Zaidi, Mone, Kim, Se-Min, Mathew, Mehr, Korkmaz, Funda, Sultana, Farhath, Miyashita, Sari, Gumerova, Anisa Azatovna, Frolinger, Tal, Moldavski, Ofer, Barak, Orly, Pallapati, Anusha, Rojekar, Satish, Caminis, John, Ginzburg, Yelena, Ryu, Vitaly, Davies, Terry F, Lizneva, Daria, Rosen, Clifford J, Yuen, Tony

“…The past decade has seen significant advances in our understanding of skeletal homeostasis and the mechanisms that mediate the loss of bone integrity in…”
Get full text

Development and biophysical characterization of a humanized FSH-blocking monoclonal antibody therapeutic formulated at an ultra-high concentration by Rojekar, Satish, Pallapati, Anusha R, Gimenez-Roig, Judit, Korkmaz, Funda, Sultana, Farhath, Sant, Damini, Haeck, Clement M, Macdonald, Anne, Kim, Se-Min, Rosen, Clifford J, Barak, Orly, Meseck, Marcia, Caminis, John, Lizneva, Daria, Yuen, Tony, Zaidi, Mone

“…Highly concentrated antibody formulations are oftentimes required for subcutaneous, self-administered biologics. Here, we report the development of a unique…”
Get full text

Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials by Pape, Ulrich-Frank, Iyer, Kishore R., Jeppesen, Palle B., Kunecki, Marek, Pironi, Loris, Schneider, Stéphane M., Seidner, Douglas L., Lee, Hak-Myung, Caminis, John

“…Background: In multiple clinical studies, teduglutide reduced parenteral support (PS) with a consistent safety profile in adults with short bowel…”
Get full text

Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis by Robinson, Martyn K., Caminis, John, Brunkow, Mary E.

“…•Sclerosteosis is a rare human high bone mass condition.•Characterisation of sclerosteosis helped identify a new bone regulatory pathway.•Rare monogenic…”
Get full text

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double‐Blind, Phase 2, Parallel Group Study by McClung, Michael R, Brown, Jacques P, Diez‐Perez, Adolfo, Resch, Heinrich, Caminis, John, Meisner, Paul, Bolognese, Michael A, Goemaere, Stefan, Bone, Henry G, Zanchetta, Jose R, Maddox, Judy, Bray, Sarah, Grauer, Andreas

“…ABSTRACT Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased bone mineral density (BMD) in…”
Get full text

Distribution and correlates of serum 25-hydroxyvitamin D levels in a sample of patients with hip fracture by Pieper, Carl F, Colon-Emeric, Cathleen, Caminis, John, Betchyk, Kathleen, Zhang, Jie, Janning, Cheri, Shostak, John, LeBoff, Meryl S, Heaney, Robert R, Lyles, Kenneth W

“…Vitamin D deficiency is common in older populations, particularly during the winter months due to low levels of ultraviolet light exposure, and in nursing home…”
Get more information

Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture: A Randomized Phase-2 Study by Bhandari, Mohit, Schemitsch, Emil H., Karachalios, Theofilos, Sancheti, Parag, Poolman, Rudolf W., Caminis, John, Daizadeh, Nadia, Dent-Acosta, Ricardo E., Egbuna, Ogo, Chines, Arkadi, Miclau, Theodore

“…BACKGROUND:Romosozumab is an antibody that binds and inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption. A double-blinded,…”
Get full text

A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures by Schemitsch, Emil H., Miclau, Theodore, Karachalios, Theofilos, Nowak, Lauren L., Sancheti, Parag, Poolman, Rudolf W., Caminis, John, Daizadeh, Nadia, Dent-Acosta, Ricardo E., Egbuna, Ogo, Chines, Arkadi, Maddox, Judy, Grauer, Andreas, Bhandari, Mohit

“…BACKGROUND:Romosozumab is a bone-forming antibody that increases bone formation and decreases bone resorption. We conducted a double-blinded, randomized,…”
Get full text

Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study by Gold, Deborah T., Beckett, Tammy, Deal, Chad, James, Andrew L., Mohseni, Mahshid, McMillan, Abigail, Bailey, Tom, Pearman, Leny, Caminis, John, Wang, Yamei, Williams, Setareh A., Kernaghan, Jacqueline M.

“…Summary Review of medical records from 173 women with osteoporosis who received abaloparatide treatment revealed that 96.0% had at least one visit for…”
Get full text

A correlative study of ultrasound calcaneal and dual-energy X-ray absorptiometry bone measurements of the lumbar spine and femur in 1000 women by Rosenthall, L, Tenenhouse, A, Caminis, J

“…The objectives of the study were firstly to determine the accuracy of ultrasound calcaneal measurements in the prediction of bone mineral density…”
Get full text

Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures by Hiligsmann, Mickael, Silverman, Stuart L., Singer, Andrea J., Pearman, Leny, Wang, Yamei, Caminis, John, Reginster, Jean-Yves

“…Background Osteoporotic-related fractures represent an increasing burden to patients, health care systems and society. Aims This study estimated…”
Get full text

Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States by Hiligsmann, Mickaël, Silverman, Stuart S., Singer, Andrea J., Pearman, Leny, Mathew, Jake, Wang, Yamei, Caminis, John, Reginster, Jean-Yves

“…Background and Objectives Abaloparatide (ABL) significantly increases bone mineral density in men with osteoporosis similar to what was reported in…”
Get full text

Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute Bleeding Events by Pipe, Steven, Ragni, Margaret V., Négrier, Claude, Yu, Qifeng, Bajwa, Naghmana, Caminis, John, Mei, Baisong, Andersson, Shauna R.

“…Background Fitusiran is a once-monthly subcutaneously administered investigational RNA interference (RNAi) therapeutic targeting antithrombin (AT) to enhance…”
Get full text

Effects of Abaloparatide or Placebo on Bone Mineral Density in Acetabular Regions Corresponding to DeLee and Charnley Zones in Postmenopausal Women with Osteoporosis by Sheth, Neil P., Bostrom, Mathias P., Winzenrieth, Renaud, Humbert, Ludovic, Pearman, Leny, Caminis, John, Wang, Yamei, Boxberger, John I., Krohn, Kelly

Get full text

Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials by Hey-Hadavi, Juliana, Seekins, Daniel, Palmer, Melissa, Coffey, Denise, Caminis, John, Abdullaev, Sandzhar, Patwardhan, Meenal, Tyler, Haifa, Raheja, Ritu, Stanley, Ann Marie, Pineda-Salgado, Liliam, Bourdet, David L., Andrade, Raul J., Hayashi, Paul H., Dimick-Santos, Lara, Rockey, Don C., Estilo, Alvin

“…Causality assessment for suspected drug-induced liver injury (DILI) during drug development and following approval is challenging. The IQ DILI Causality…”
Get full text

Optimizing a therapeutic humanized follicle‐stimulating hormone–blocking antibody formulation by protein thermal shift assay by Sant, Damini, Rojekar, Satish, Gera, Sakshi, Pallapati, Anusha R., Gimenez‐Roig, Judit, Kuo, Tan‐Chun, Padilla, Ashley, Korkmaz, Funda, Cullen, Liam, Chatterjee, Jiya, Shelly, Eleanor, Meseck, Marcia, Miyashita, Sari, Macdonald, Anne, Sultana, Farhath, Barak, Orly, Ryu, Vitaly, Kim, Se‐Min, Robinson, Cemre, Rosen, Clifford J., Caminis, John, Lizneva, Daria, Haider, Shozeb, Yuen, Tony, Zaidi, Mone

“…Biopharmaceutical products are formulated using several Food and Drug Administration (FDA) approved excipients within the inactive ingredient limit to maintain…”
Get full text

FRI682 Cost Effectiveness Of Four Treatment Approaches For US Women And Men At Very High Risk Of Osteoporotic Fractures by Hiligsmann, Mickael, Silverman, Stuart, Singer, Andrea J, Pearman, Leny, Wang, Yamei, Caminis, John N, Reginster, Jean-Yves

“…Disclosure: M. Hiligsmann: Grant Recipient; Self; Radius Health, Inc. S. Silverman: Consulting Fee; Self; Amgen Inc, Radius Health, Inc. Grant Recipient; Self;…”
Get full text

FSH-blocking therapeutic for osteoporosis by Gera, Sakshi, Kuo, Tan-Chun, Gumerova, Anisa Azatovna, Korkmaz, Funda, Sant, Damini, DeMambro, Victoria, Sudha, Karthyayani, Padilla, Ashley, Prevot, Geoffrey, Munitz, Jazz, Teunissen, Abraham, van Leent, Mandy M T, Post, Tomas G J M, Fernandes, Jessica C, Netto, Jessica, Sultana, Farhath, Shelly, Eleanor, Rojekar, Satish, Kumar, Pushkar, Cullen, Liam, Chatterjee, Jiya, Pallapati, Anusha, Miyashita, Sari, Kannangara, Hasni, Bhongade, Megha, Sengupta, Puja, Ievleva, Kseniia, Muradova, Valeriia, Batista, Rogerio, Robinson, Cemre, Macdonald, Anne, Hutchison, Susan, Saxena, Mansi, Meseck, Marcia, Caminis, John, Iqbal, Jameel, New, Maria I, Ryu, Vitaly, Kim, Se-Min, Cao, Jay J, Zaidi, Neeha, Fayad, Zahi A, Lizneva, Daria, Rosen, Clifford J, Yuen, Tony, Zaidi, Mone

“…Pharmacological and genetic studies over the past decade have established the follicle-stimulating hormone (FSH) as an actionable target for diseases affecting…”
Get full text

7933 Baseline Demographics and Design of the SkybriGHt Registry Study. A US Multi-center, Prospective, Non-interventional, Long-term, Effectiveness and Safety Study of Children and Adolescents with Growth Hormone Deficiency Treated with Lonapegsomatropin by Backeljauw, Philippe Ferdinand, Maniatis, Aristides K, Jennifer Abuzzahab, M, Chernausek, Steven D, Lipman, Terri, Dewan, Asheesh Kumar, Prakasam, Gnanagurudasan, Kabbani, Mahmoud B, Huang, Eric, Lai, Pamela, Raveendran, Subhara, Zhao, Carol, Caminis, John N, Rogol, Alan D

“…Disclosure: P.F. Backeljauw: Advisory Board Member; Self; Ascendis Pharma, Inc., Novo Nordisk, BioMarin. Consulting Fee; Self; Ascendis Pharma, Inc., Novo…”
Get full text